0I1B Stock Overview
Operates as a medical technology company focus on developing clinically differentiated solutions worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Enovis Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$45.18 |
| 52 Week High | US$64.85 |
| 52 Week Low | US$38.55 |
| Beta | 2 |
| 11 Month Change | 12.89% |
| 3 Month Change | 4.49% |
| 1 Year Change | -11.52% |
| 33 Year Change | -69.89% |
| 5 Year Change | -55.00% |
| Change since IPO | -63.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0I1B | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | -2.8% | -1.6% | 0.8% |
| 1Y | -11.5% | -4.4% | 6.6% |
Return vs Industry: 0I1B underperformed the UK Medical Equipment industry which returned -4% over the past year.
Return vs Market: 0I1B underperformed the UK Market which returned 6.1% over the past year.
Price Volatility
| 0I1B volatility | |
|---|---|
| 0I1B Average Weekly Movement | 6.3% |
| Medical Equipment Industry Average Movement | 6.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0I1B has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0I1B's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 6,550 | Matt Trerotola | www.enovis.com |
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
Enovis Corporation Fundamentals Summary
| 0I1B fundamental statistics | |
|---|---|
| Market cap | US$2.50b |
| Earnings (TTM) | -US$121.38m |
| Revenue (TTM) | US$2.00b |
1.3x
P/S Ratio-20.6x
P/E RatioIs 0I1B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0I1B income statement (TTM) | |
|---|---|
| Revenue | US$2.00b |
| Cost of Revenue | US$821.68m |
| Gross Profit | US$1.18b |
| Other Expenses | US$1.30b |
| Earnings | -US$121.38m |
Last Reported Earnings
Sep 27, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.17 |
| Gross Margin | 58.95% |
| Net Profit Margin | -6.06% |
| Debt/Equity Ratio | 40.4% |
How did 0I1B perform over the long term?
See historical performance and comparison